Posted by Michael Wonder on 17 Mar 2020
Mallinckrodt completes rolling submission of new drug application to the U.S. FDA for terlipressin for the treatment of patients with hepatorenal syndrome type 1
17 March 2020 - Terlipressin would be the first FDA approved treatment option in the United States for adult patients with HRS-1, a life-threatening condition, if approved.
Mallinckrodt today announced the completion of its rolling submission of a new drug application to the U.S. FDA for terlipressin, an investigational agent being evaluated for the treatment of hepatorenal syndrome type 1.
The company previously announced the rolling submission, which it initiated in February.
